Video

Dr. Berg highlights key ongoing trials in urothelial cancer

Author(s):

Urology Times staff

Stephanie Berg, DO, highlights key ongoing trials in advanced/metastatic urothelial cancer, including EV-302 (NCT04223856), NILE (NCT03682068) CheckMate-901 (NCT03036098), and MAIN-CAV (NCT05092958).Berg is an instructor of medicine, Harvard Medical School, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute.

Related Videos
Suzanne B. Merrill, MD, FACS, answers a question during a Zoom video interview
Urinary bladder | Image Credit: © magicmine - stock.adobe.com
3d rendered illustration - bladder cancer | Image Credit: © Sebastian Kaulitzki - stock.adobe.com
Betty Wang, MD, discusses studies from the 2025 EAU meeting
Joshua J. Meeks, MD, PhD, answers a question during a Zoom video interview
Human urinary bladder | Image Credit: © magicmine - stock.adobe.com
Related Content
Human Body Organs (Urinary Bladder) | Image Credit: @ magicmine - stock.adobe.com
April 21st 2025

Nadofaragene firadenovec elicits high CR rate in phase 3 trial in Japan

Hannah Clarke
Treatment with nadofaragene led to a complete response rate of 75% at 3 months.
medical depiction of bladder cancer
May 31st 2023

Bladder Cancer Awareness Month: Dr. Kamat highlights the state of bladder cancer care

Urology Times staff
In this episode, Ashish M. Kamat, MD, MBBS, highlights the state of bladder cancer care in recognition of Bladder Cancer Awareness Month.
3d rendered illustration - bladder cancer | Image Credit: © Sebastian Kaulitzki - stock.adobe.com
April 17th 2025

NMIBC Clinical Forums highlight novel therapies and treatment strategies

Urology Times staff
Two recent Clinical Forum discussions sought to examine how emerging therapeutic options and evolving treatment standards in non–muscle invasive bladder cancer affect clinical practices and patient outcomes.
Speaking of Urology Podcast: Dr. Ritch and Dr. Katz discuss new bladder cancer management app
December 7th 2021

Speaking of Urology Podcast: Dr. Ritch and Dr. Katz discuss new bladder cancer management app

Urology Times staff
“It's not a replacement for clinical judgment, obviously. But at the end of the day, the idea is that it shows you what your next steps are based on what the American Urological Association and [Society of Urologic Oncology] guidelines are for non-muscle invasive bladder cancer,” Chad R. Ritch, MD, MBA, FACS.
FDA approval sought for Anktiva in papillary NMIBC
April 15th 2025

FDA approval sought for Anktiva in papillary NMIBC

Hannah Clarke
The sBLA is supported by data from cohort B of the pivotal QUILT-3.032 trial.
What urologists can expect in Q2 of 2025
April 7th 2025

What urologists can expect in Q2 of 2025

Hannah Clarke Benjamin P. Saylor
A lookahead of the notable FDA decisions and conferences slated for Q2 2025.
© 2025 MJH Life Sciences

All rights reserved.